New Mount Sinai Research Brings Hope for Small Cell Lung Cancer Patients
Researchers at the Icahn School of Medicine at Mount Sinai have made a promising breakthrough in the treatment of small cell lung cancer (SCLC). Their study, published in Science Advances, on September 27 and titled “ATR Inhibition Activates Cancer Cell cGAS/STING-Interferon Signaling and Promotes Anti-Tumor Immunity in Small Cell Lung Cancer,” presents an exciting new approach that offers hope to patients with this challenging disease.
Small cell lung cancer is one of the most aggressive types of cancer. It represents about 10 to 15 percent of all lung cancer cases in the United States, with roughly 30,000 to 35,000 new cases each year. Unfortunately, by the time most patients are diagnosed, the cancer has often spread, making it difficult to treat. Current treatments, such as chemotherapy and immunotherapy, offer only temporary relief, and the five-year survival rate is less than 10 percent.
“We’ve concentrated on ATR (ataxia telangiectasia and Rad3-related protein), which plays a key role in repairing DNA in cancer cells. By inhibiting ATR, we make these cancer cells more vulnerable to treatments and enhance the immune system’s ability to target them,” said Triparna Sen, PhD, Associate Professor of Oncological Sciences, and the Director of the Lung Cancer PDX Platform, at Icahn Mount Sinai.
New Treatment Strategy: One-Two Punch
The study explored the effects of a new drug called berzosertib (M6620/VX970) combined with another drug, topotecan, to treat SCLC patients who have relapsed.
“Our findings suggest that this combination could be very effective, especially for patients whose cancer has returned,” Dr. Sen noted. The research also suggests that using ATR inhibitors along with anti-PD-L1 antibodies, type of targeted immunotherapy called an immune checkpoint inhibitor that help the immune system recognize and attack cancer cells, might improve outcomes even further.
The study showed that inhibiting ATR activates a part of the immune system known as the cGAS-STING pathway. This leads to an increase in immune signals like interferons and chemokines, which help the immune system detect and attack cancer cells more effectively.
“We have previously established that DNA damage response proteins are effective targets for small cell lung cancer and this research, co-led by postdocs Hirokazu Taniguchi, MD, PhD, and Subhamoy Chakraborty,PhD, is a significant advancement in treating small cell lung cancer. By targeting ATR and enhancing the immune response, we are opening up new possibilities for better treatment options,” Dr. Sen explained.
The Mount Sinai team plans to propose a clinical trial to test these new treatments by 2025. They hope this research will also benefit other hard-to-treat cancers.
Dr. Sen’s research is now featured in Science Advances, a prominent journal. She and her team have already presented these findings at major conferences, including at the European Society of Molecular Oncology meeting in Barcelona earlier in September.
Mount Sinai’s groundbreaking research not only brings new hope to patients with small cell lung cancer but also highlights the institution’s commitment to advancing cancer treatments. As research progresses, studies like this are crucial for developing innovative therapies and improving the lives of patients facing severe health challenges.
This study included investigators from Memorial Sloan Kettering Cancer Center and the National Institutes of Health (NIH). The clinical study of Berzosertib and Topotecan was conducted at NIH and the Principal Investigator was Anish Thomas, MBBS, MD, who is a co-author in the manuscript.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.